(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 117.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Intellia Therapeutics's revenue in 2025 is $45,569,000.On average, 9 Wall Street analysts forecast NTLA's revenue for 2025 to be $5,799,530,647, with the lowest NTLA revenue forecast at $932,250,546, and the highest NTLA revenue forecast at $21,752,512,740. On average, 9 Wall Street analysts forecast NTLA's revenue for 2026 to be $4,411,306,000, with the lowest NTLA revenue forecast at $932,250,546, and the highest NTLA revenue forecast at $10,358,339,400.
In 2027, NTLA is forecast to generate $60,206,190,428 in revenue, with the lowest revenue forecast at $378,079,388 and the highest revenue forecast at $392,188,482,197.